NSCLC
Conditions
Interventions
Neurocognitive adverse events will be evaluated by standardized neurocognitive tests that cover the most important domains of neurocognition. All the tests will be performed at baseline (i.e. maximum
Sponsors
academisch ziekenhuis maastricht
Eligibility
Inclusion criteria
Inclusion criteria: - Stage IV NSCLC with ALK or ROS1 rearrangement, indication in daily clinical care to start lorlatinib treatment - Age ≥ 18 years - Ability to understand neurocognitive testing - Written informed consent
Exclusion criteria
Exclusion criteria: - Neurodegenerative diseases (such as Alzheimers disease) - Psychiatric disease - Symptomatic brain metastases / neurological symptoms due to previous cranial irradiation (e.g. due to radiation necrosis) - Inability to understand the testing / questionnaires
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -change for every neurocognitive endpoint during treatment with lorlatinib compared to baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| - Correlation of neurocognitive impairment on the neurocognitive tests to the self-reported neurocognitive impairment - Correlation of neurocognitive impairment on the neurocognitive tests to the CTCAE scored neurocognitive impairment | — |
Contacts
Public ContactL. Hendriks
Dept of Pulmonary Diseases, MUMC+ PO Box 5800
Outcome results
None listed